Drug Approval | December 25, 2023
Eugia's East Windsor facility gets 10 observations from USFDA
The plant is yet to start commercial operations
The plant is yet to start commercial operations
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
10+ emerging markets, Japan & ANZ transition in final phase
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Fischer Chemic will make an entry into the growing market of diagnostic imaging industry with innovative and disruptive technologies
Subscribe To Our Newsletter & Stay Updated
